Cannara Biotech Inc. Reports Fiscal Second Quarter 2022 Financial Results
April 27th, 2022
News, Top News
Company recorded $7.4 million in quarterly revenues and delivers fourth consecutive quarter of positive Adjusted EBITDA while continuing to rapidly scale production capacity at the Valleyfield Facility
Completed first harvest from the Valleyfield Facility with positive market feedback consistent with the quality of products Cannara is known for
All financial results are reported in Canadian dollars, unless otherwise stated.
MONTREAL, April 27, 2022 /PRNewswire/ – Cannara Biotech Inc. (“Cannara” or the “Company“) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically integrated producer of premium-grade cannabis and derivative products with two mega facilities based in Québec spanning over 1,650,000 sq. ft., today announced its fiscal second quarter 2022 financial and operating results for the three and six-month periods ended February 28, 2022.
Fiscal Second Quarter 2022 Financial and Operational Highlights
- Posted quarterly revenues of $7.4 million, an increase of 229% from the same quarter in the previous year;
- Recorded a gross profit before fair value adjustments of $2.6 million or 36% more than the same quarter in the previous year;
- Achieved fourth consecutive quarter of positive Adjusted EBITDA while significantly expanding its production footprint within the facility located in Valleyfield, Québec (the “Valleyfield Facility”). Revenues from the Valleyfield Facility will start to be realized in the third quarter of 2022;
- Positive Adjusted EBITDA of $1 million for the first six months of 2022 while supporting over $1 million in startup expenses for the Valleyfield Facility compared to a negative Adjusted EBITDA of $(2.4) million in the same period of prior year;
- Successfully harvested its first growing zone in its newly redesigned Valleyfield Facility and has sold, subsequent to quarter-end, the finished product generated from this first harvest;
- Completed the activation of its second and third 25,000 square foot growing zones in the Valleyfield Facility, effectively increasing its overall production capacity by more than 200% when comparing to the production capacity at its Farnham Facility;
- Increased working capital to $14.8 million from a working capital of $12.4 million as at August 31, 2021;
- Invested $7.4 million in capital expenditures towards the Company’s assets in order to increase production capacity and processing capabilities;
- Granted an aggregate total of 7,710,000 stock options to certain employees and 225,000 stock options to board members at an exercise price of $0.18 per common share, subject to certain vesting conditions.
Highlights Subsequent to Quarter End
- Introduced a new genetic strain under the Tribal brand to the Quebec market: Terple. The product is available in a 3.5g can and five 0.5g pre-rolls;
- The Company completed the activation of its fourth 25,000 square foot growing zone and is currently ahead of its objective of activating 6 growing zones by August 2022;
- The Company was selected as one of only three cannabis producers by the Ontario Cannabis Store (“OCS”) to have a headlining product for their 420 event; To support this, the Company created a special edition of its Early Lemon Berry pre-rolls, offering a 12 x 0.6g joint format with innovative packaging design;
- The Company successfully harvested its second growing zone at its Valleyfield Facility;
- Granted an aggregate total of 600,000 stock options to certain employees at an exercise price of $0.18 per common share, subject to certain vesting conditions;
- Exercise of 500,000 stock options at an exercise price of $0.10 for a total proceed of $50,000.
“We are proud of the advances we made in the second quarter. We planted three 25,000 square foot growing zones and successfully harvested our first zone in February,” commented Zohar Krivorot, President & Chief Executive Officer of Cannara. “By redesigning the Valleyfield Facility and receiving consistent positive consumer feedback on our first harvest, we have successfully confirmed our ability to grow premium cannabis at scale. Our objective for the year is to turn on six growing zones by August 2022 at Valleyfield and we remain on schedule to do so”.
Nicholas Sosiak, Chief Financial Officer of Cannara commented, “While we are focused on investing into our own assets, we continue to outperform from a financial standpoint. This was our fourth consecutive quarter of positive Adjusted EBITDA while continuing to support and significantly grow our production footprint. We added over 40 new employees to help support the growth at the Valleyfield Facility yet the revenues from this Facility will only start to be realized in the third quarter of 2022. We are working extremely hard this quarter and next to expand our distribution channels and get products listed in new markets. I am looking forward to the coming quarters as we harvest and sell our products from the new operating zones at our Valleyfield Facility and expand our footprint into new markets across Canada.”
|Three-month periods ended||Six-month periods ended|
|Selected Financial Highlights||February 28,
|Gross revenue1||$ 7,272,059||$ 1,969,103||$ 13,599,394||$ 3,303,441|
|Gross profit, before fair value adjustments||2,635,607||1,298,261||5,649,632||1,794,407|
|Gross profit (loss)||3,015,577||2,095,208||5,635,619||1,597,849|
|Net finance expense||772,996||451,951||1,320,250||789,062|
|Net income (loss)||$ (1,145,823)||$ (862,756)||(1,676,322)||(4,357,788)|
|Adjusted EBITDA5||$ 33,998||$ (850,509)||1,008,319||(2,423,630)|
|Basic earnings (loss) per share||$ (0.01)||$ (0.01)||$ (0.01)||$ (0.01)|
|Diluted earnings (loss) per share||$ (0.01)||$ (0.01)||$ (0.01)||$ (0.01)|
|February 28, 2022||August 31, 2021|
|Cash||$ 8,258,006||$ 8,159,305|
|Total current liabilities||7,910,429||6,833,798|
|Total non-current liabilities||31,237,792||21,073,003|
|1 Gross revenue included revenue from sale of goods, net of excise taxes, services revenues and lease revenues.|
|2 Gross profit before fair value adjustments % is determined as Gross profit before fair value adjustments divided by Total revenues.|
|3 Gross profit (loss) % is determined as Gross profit (loss) divided by Total revenues.|
|4 Net income (loss) % is determined as Net income (loss) divided by Total revenues.|
|5 Adjusted EBITDA and working capital are non-GAAP financial performance measures with no standard definition under IFRS.
A reconciliation of these measures is presented elsewhere in this MD&A.
|Adjusted EBITDA % a non-GAAP financial ratio and is determined as Adjusted EBITDA divided by total revenues.|
|6 Working capital is determined as total current assets minus total current liabilities.|
|Three-month periods ended||Six-month periods ended|
|Adjusted EBITDA||February 28,
|Net loss||$ (1,145,823)||$ (862,756)||$ (1,676,322)||$ (4,357,788)|
|Changes in fair value of inventory sold||1,269,679||447,885||3,136,159||651,195|
|Unrealized gain on changes in fair value of biological assets||(1,649,649)||(1,244,832)||(3,122,146)||(454,637)|
|Amortization, including amortization in cost of good sold||629,027||251,634||1,221,586||738,290|
|Loss on disposal of property, plant and equipment||6,444||54,224||31,106||54,224|
|Gain on sublease||–||–||(12,876)||–|
|Share-based compensation, including share-based
compensation in cost of good sold
|Net finance expense||772,996||451,951||1,320,250||789,062|
|Adjusted EBITDA1||$ 33,998||$ (850,509)||$ 1,008,319||$ (2,423,630)|
|1 Adjusted EBITDA is a non-GAAP financial performance measure with no standard definition under IFRS.|
As at the date of this report, the Company had 876,981,321 common shares and 40,645,781 stock options issued and outstanding. For further information, the complete Condensed Interim Consolidated Financial Statements and Management’s Discussion and Analysis for the three and six-month periods ended February 28, 2022 and 2021, along with additional information about the Company and all of its public filings are available at sedar.com and the Company’s investor website, investors.cannara.ca.
About Cannara Biotech Inc.
Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB) is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for the Québec and Canadian markets. Cannara owns two mega facilities based in Québec spanning over 1,650,000 sq. ft., providing the Company with 125,000kg of potential annualized cultivation output. Leveraging Québec’s low electricity costs, Cannara’s facilities produce premium-grade cannabis products at an affordable price. For more information, please visit cannara.ca.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding “Forward-Looking” Information
This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.